Latest Pharmaceuticals News

BTC Health has transformed its decade-long license agreement with Arna Pharma into an indefinite partnership, gaining royalties from Singapore and Malaysia sales and first rights to new pharmaceutical products in Australia and New Zealand.

CLINUVEL has released preliminary data from its CUV052 study showing SCENESSE® is well tolerated in adolescent erythropoietic protoporphyria (EPP) patients, supporting a planned label extension in 2025.

Mayne Pharma reports a robust first half of FY25 with revenues climbing to $210-$215 million and underlying EBITDA soaring by up to 300%, driven by strong performance in Women's Health.

Neuren Pharmaceuticals has received a significant cash inflow of approximately US$50 million following the sale of a Priority Review Voucher linked to its Rett syndrome treatment. This milestone underscores the growing value of Neuren’s neurological drug portfolio and its partnership with Acadia Pharmaceuticals.

Nyrada has secured ethics approval to begin its first-in-human Phase Ia trial of NYR-BI03, a promising neuro- and cardioprotective drug candidate. Recruitment starts soon, with dosing expected by March and results due in Q3 2025.

Sigma Healthcare has raised its FY25 normalised EBIT guidance to $64-$70 million, driven by robust operational performance and the successful rollout of a key supply contract with Chemist Warehouse.

Acrux Limited announces the retirement of CEO Michael Kotsanis after more than 10 years at the helm, with a search underway for his successor to lead the next phase of growth.

Neuren Pharmaceuticals has secured a pivotal FDA Type C Meeting to discuss primary efficacy endpoints for its Phase 3 trial of NNZ-2591 targeting Phelan-McDermid syndrome, advancing its rare disease drug development.

Actinogen Medical has published a peer-reviewed article confirming the efficacy of a 10 mg daily dose of Xanamem for treating neurological conditions, reinforcing its ongoing clinical trials in Alzheimer's and depression.

Neurizon Therapeutics has been granted a pivotal US patent for its lead drug candidate NUZ-001, extending protection until 2039 and enhancing its commercial and clinical positioning in neurodegenerative disease treatment.

Sigma Healthcare has secured Federal Court approval for its acquisition of Chemist Warehouse, marking a pivotal step in reshaping Australia's pharmaceutical retail landscape.

Wellnex Life has secured Therapeutic Goods Administration approval for its Liquid Paracetamol plus Caffeine Soft Gel, marking its fourth market authorisation and opening new revenue avenues.